Guest post by Manasi Vaidya, Healthcare Reporter at BioPharm Insight
This year’s annual American Society of Clinical Oncology (ASCO) meeting left us with much to ponder on the constantly evolving field of cancer treatments.
Navigating through more than 37,000 attendees, BioPharm Insight was on-site to garner fast-breaking trial updates from expert sources and in-depth analyses of various drugs in development. Thought leaders not only discussed emerging therapies, but also debated the current drug pricing models and their impact on patient quality of life.
Immunotherapy was the buzzword this year, with PD-1 and PDL-1 inhibitors dominating the limelight. While durable responses in melanoma gave oncologists something to cheer about, they highlighted the need for reliable biomarkers and measures to address combination related toxicities in other indications like non-small cell lung cancer and renal cell carcinoma. Non-small cell lung cancer specialists especially emphasized the manner in which an accurate biomarker will affect the uptake of these therapies. Emerging CAR-T therapies too faced similar concerns of toxicity management, with experts saying that current investigational therapies generally have similar efficacies.
While ASCO didn’t feature practice changing data release in gynecological cancers, physicians pointed to the progress with PARP inhibitors, and the impact of recent approvals of targeted agents in breast cancer.
The BioPharm Insight ASCO post-conference report showcases 27 investigative news articles written by Alaric DeArment, Hamish McDougall, Katie McQue and Manasi Vaidya, that analyzed the impact of the clinical data released at ASCO across a number of oncology indications. To view the report, please click here for a free trial with BPI.
To request a trial of BioPharm Insight, please click here.
Cancer immunotherapies is just one of many hot topics on the program at BioPharm America™ this September.